Kaiser Permanente Washington Health Research Institute, Seattle.
Department of Health Systems and Population Health, University of Washington, Seattle.
JAMA Netw Open. 2022 May 2;5(5):e2211677. doi: 10.1001/jamanetworkopen.2022.11677.
Patients who use cannabis for medical reasons may benefit from discussions with clinicians about health risks of cannabis and evidence-based treatment alternatives. However, little is known about the prevalence of medical cannabis use in primary care and how often it is documented in patient electronic health records (EHR).
To estimate the primary care prevalence of medical cannabis use according to confidential patient survey and to compare the prevalence of medical cannabis use documented in the EHR with patient report.
DESIGN, SETTING, AND PARTICIPANTS: This study is a cross-sectional survey performed in a large health system that conducts routine cannabis screening in Washington state where medical and nonmedical cannabis use are legal. Among 108 950 patients who completed routine cannabis screening (between March 28, 2019, and September 12, 2019), 5000 were randomly selected for a confidential survey about cannabis use, using stratified random sampling for frequency of past-year use and patient race and ethnicity. Data were analyzed from November 2020 to December 2021.
Survey measures of patient-reported past-year cannabis use, medical cannabis use (ie, explicit medical use), and any health reason(s) for use (ie, implicit medical use).
Survey data were linked to EHR data in the year before screening. EHR measures included documentation of explicit and/or implicit medical cannabis use. Analyses estimated the primary care prevalence of cannabis use and compared EHR-documented with patient-reported medical cannabis use, accounting for stratified sampling and nonresponse.
Overall, 1688 patients responded to the survey (34% response rate; mean [SD] age, 50.7 [17.5] years; 861 female [56%], 1184 White [74%], 1514 non-Hispanic [97%], and 1059 commercially insured [65%]). The primary care prevalence of any past-year patient-reported cannabis use on the survey was 38.8% (95% CI, 31.9%-46.1%), whereas the prevalence of explicit and implicit medical use were 26.5% (95% CI, 21.6%-31.3%) and 35.1% (95% CI, 29.3%-40.8%), respectively. The prevalence of EHR-documented medical cannabis use was 4.8% (95% CI, 3.45%-6.2%). Compared with patient-reported explicit medical use, the sensitivity and specificity of EHR-documented medical cannabis use were 10.0% (95% CI, 4.4%-15.6%) and 97.1% (95% CI, 94.4%-99.8%), respectively.
These findings suggest that medical cannabis use is common among primary care patients in a state with legal use, and most use is not documented in the EHR. Patient report of health reasons for cannabis use identifies more medical use compared with explicit questions about medical use.
因医疗原因使用大麻的患者可能会受益于与临床医生就大麻的健康风险和基于证据的替代治疗方法进行讨论。然而,对于初级保健中医疗用大麻使用的流行程度以及其在患者电子健康记录 (EHR) 中记录的频率,我们知之甚少。
根据机密患者调查估计医疗用大麻使用的初级保健流行率,并将 EHR 中记录的医疗用大麻使用与患者报告进行比较。
设计、设置和参与者:本研究是一项横断面调查,在一个在华盛顿州进行常规大麻筛查的大型医疗系统中进行,该州医疗和非医疗用大麻均合法。在完成常规大麻筛查的 108950 名患者中(2019 年 3 月 28 日至 2019 年 9 月 12 日),随机抽取 5000 名患者进行关于大麻使用的机密调查,对过去一年的使用频率以及患者种族和族裔进行分层随机抽样。数据分析于 2020 年 11 月至 2021 年 12 月进行。
调查措施包括患者报告的过去一年大麻使用、医疗用大麻使用(即明确的医疗使用)和任何健康原因(即隐含的医疗使用)。
调查数据与筛查前一年的 EHR 数据相关联。EHR 措施包括明确和/或隐含的医疗用大麻使用的记录。分析估计了大麻使用的初级保健流行率,并比较了 EHR 记录的与患者报告的医疗用大麻使用,考虑了分层抽样和无应答。
总体而言,1688 名患者对调查做出了回应(34%的回应率;平均[SD]年龄为 50.7[17.5]岁;861 名女性[56%],1184 名白人[74%],1514 名非西班牙裔[97%],1059 名商业保险[65%])。调查中任何过去一年患者报告的大麻使用的初级保健流行率为 38.8%(95%CI,31.9%-46.1%),而明确和隐含的医疗使用的流行率分别为 26.5%(95%CI,21.6%-31.3%)和 35.1%(95%CI,29.3%-40.8%)。EHR 记录的医疗用大麻使用的流行率为 4.8%(95%CI,3.45%-6.2%)。与患者报告的明确医疗使用相比,EHR 记录的医疗用大麻使用的敏感性和特异性分别为 10.0%(95%CI,4.4%-15.6%)和 97.1%(95%CI,94.4%-99.8%)。
这些发现表明,在一个合法使用大麻的州,医疗用大麻在初级保健患者中很常见,并且大多数使用情况并未在 EHR 中记录。与明确询问医疗用途相比,患者报告大麻使用的健康原因可以识别更多的医疗用途。